Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for LY294002 (compound)
Most Correlated Studies
- Treated keratinocyte HaCaT cell line overexpressing EGFR, RELA (p65), or HRAS-VAL12D
- Oncogenic PI3K mutations in cancer cells following growth factor deprivation
- Breast epithelial cells that are organized and disorganized in cell culture
- Embryonic EBRTcH3 stem cells with or without MYC(T58A) overexpression treated with LY294002
- CD4+ T cells age and culture condition comparisons treated with rapamycin or LY 294002
Most Relevant Literature
- LY294002, a PI3K inhibitor, attenuates Tourette syndrome in rats.
- Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling …
- Inhibitory Effect of LY294002 on Proliferation of Multiple Myeloma Cells and Its Mechanism].
- LY294002 prevents lipopolysaccharide‑induced hepatitis in a murine model by suppressing IκB phosphor…
- Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanom…
Most Relevant Clinical Trials
- SF1126 for Patients With Relapsed or Refractory Neuroblastoma
- Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
- Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
- GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastat…
